Dudediligence.

Adaptive Biotechnologies Corporation

ADPTNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$46.4MSep ’24$47.5MDec ’24$52.4MMar ’25$58.9MJun ’25$94.0MSep ’25$71.7MDec ’25$70.9MMar ’26$71.6MJun ’26
Net income, by quarter
−$32.1MSep ’24−$33.7MDec ’24−$29.9MMar ’25−$25.6MJun ’25$9.5MSep ’25−$13.6MDec ’25−$20.0MMar ’26−$39.8MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$154.3M$185.3M$170.3M$179.0M$277.0M
Gross profit$105.0M$127.4M$94.7M$106.9M$205.6M
Operating income−$209.0M−$200.2M−$227.0M−$162.5M−$57.1M
Net income−$207.3M−$200.2M−$225.3M−$159.5M−$59.5M
Operating cash flow−$192.7M−$183.9M−$156.3M−$95.2M−$46.0M
Free cash flow−$254.5M−$200.3M−$167.0M−$98.9M−$48.9M
Cash$139.1M$90.0M$65.1M$47.9M$70.5M
Debtnone on file$125.4M$130.7M$133.3M$131.2M
Shares outstanding141.4M143.1M145.1M147.8M153.8M